Volume 10, Issue 02, February 2024,
Publish Date: 08-02-2024
Doi https://doi.org/10.55640/ijmsdh-10-02-16

International Journal of Medical Science and Dental Health (Open Access)

ADVANCES IN CANCER IMMUNOTHERAPY: A COMPREHENSIVE REVIEW OF CURRENT AND FUTURE APPROACHES IN THE TREATMENT OF SOLID AND HEMATOLOGIC TUMORS.

GABRIELA PATRICIA GUIJARRO REINOSO[1], NATHALY PAOLA CASTRO MOSCOSO[2], PAULA DOMÉNICA ASTUDILLO GOYO[3], BRYAN STEVEN PASQUEL RODRÍGUEZ[4], JEFFERSON VICENTE URVINA MUÑOZ[5]

[1]*Specialist In Family and Community Medicine, Centro de Salud Totoras- Ambato, Ecuador.*

[2]*Physician, Universidad Central del Ecuador, Ecuador.*

[3]*Physician, Universidad de Cuenca, Ecuador.*

[4]*Physician, Universidad de las Americas, Ecuador.*

[5]*Physician, Universidad de Guayaquil, Ecuador.*

ABSTRACT

Cancer immunotherapy uses the patient's immune system to fight cancerous cells with little to no side effects, making it a viable treatment option for solid and hematologic cancers. Reviewing current developments as well as potential directions for the field of cancer immunotherapy, this paper focuses on immune checkpoint inhibitors (ICI), chimeric antigen receptor (CAR) T-cell treatment, and cancer vaccines. A thorough analysis of the literature using publications from 2018 to 2023 was carried out using PubMed, Scopus, and Google Scholar. The findings demonstrate the immune checkpoint inhibitors' outstanding effectiveness in treating a variety of cancers, especially when combined with anti-PD-1 and anti-CTLA-4 antibodies, which result in improved survival rates and long-lasting effects. In hematologic malignancies, CAR T-cell therapy—particularly second-generation designs—has shown encouraging results, producing notable responses in patients with relapsed or resistant illness. Cancer vaccines that target tumor-specific antigens have shown promise in enhancing T-cell responses, despite obstacles such autoreactive immune responses and tumor heterogeneity. Notwithstanding these developments, there are still several drawbacks, such as immune-related adverse effects, inconsistent response rates, and logistical challenges. According to future views, in order to overcome these obstacles and improve treatment success, new combination treatments, biomarker-driven strategies, and creative delivery methods are necessary.

KEYWORDS: Cancer, Immunotherapy, Hematologic Tumors.

INTRODUCTION

Uncontrolled cell proliferation is a condition known as cancer. Maintaining proliferative signalling, being immune system-evading, resistant to growth-suppressive signals, exhibiting infinite replication capacity, encouraging angiogenesis, inducing invasion and metastasis, reprogramming cellular and environmental metabolism, and avoiding apoptosis are some characteristics that set cancer cells apart from healthy cells (Wang, Xie, and Liu 2021). Cancer cells are immune to cell cycle regulatory systems and are able to evade apoptosis due to genetic alterations. Environmental and genetic changes have a crucial influence in the development of cancer. Physical carcinogens like ionizing and UV radiation, chemical carcinogens like alcohol intake, smoking, and asbestos exposure, and food ingestion of aflatoxin and arsenic are some of these variables. Approximately one-third of cancer fatalities are connected to smoking, alcohol use, high body mass index, bad food, and inadequate physical activity. Biological carcinogens, such as infections from certain bacteria, viruses, or parasites, are also among the causes of cancer deaths (Ferlay et al. 2021).

Cancer is a major worldwide health concern with a high incidence and fatality rate even in the modern period, despite improved medicines and early detection techniques. The World Health Organisation estimates that one in six fatalities in 2020 and around 10 million deaths overall are expected to be related to cancer. While lung, prostate, colon, stomach, and liver cancer are more prevalent in males, breast, colorectal, lung, thyroid, and cervical cancers are more common in women. While skin and stomach, lung, colon and rectum, liver, stomach, and breast cancers are the most frequent cancer types in terms of newly diagnosed cases in 2020, cancer fatalities from these diseases account for the majority of cancer-related deaths in 20205 (Miller et al. 2022).

The majority of cancer research is focused on creating better medicines to lower the mortality rates, even if there is a drop in the death rates in many cancer types owing to successful treatment approaches. With a greater knowledge of the molecular pathways behind cancer, cancer therapy has altered and progressed. Globally, there are growing issues associated with the rising number of cancer patients. On the other hand, research into the best therapy with the greatest response rate and the fewest adverse effects is still ongoing. The following cancer treatment modalities are used in the clinic: stem cell transplantation, photodynamic therapy, photodynamic therapy, radiotherapy, chemotherapy, surgery, and immunotherapy (Miller et al. 2022). Because of the ways in which these medicines generate resistance in cancer, they are often used in combination. Reviewing current developments as well as potential directions for the field of cancer immunotherapy, this paper focuses on immune checkpoint inhibitors (ICI), chimeric antigen receptor (CAR) T-cell treatment, and cancer vaccines.

METHODS

An integrated methodology is used in this thorough analysis to methodically collect and assess pertinent data from scholarly databases, such as Google Scholar, PubMed, and Scopus. The approach is modified to consider the complexity of cancer immunotherapy by using tried-and-true methods from comparable review research. The literature search makes use of important terms like "immune checkpoint inhibitors," "CAR T-cell therapy," "cancer immunotherapy," and "cancer vaccines." Boolean operators (AND, OR) are used to hone search terms and concentrate on relevant content.

- **Inclusion and Exclusion Criteria:**

Articles discussing important developments in cancer immunotherapy, such as immune checkpoint inhibitors, CAR T-cell treatment, and cancer vaccines, that were published in English within the last five years (2018–2023) are acceptable for inclusion. Studies using non-human participants, results that aren't relevant, or insufficient methodology are all considered exclusion criteria. After a preliminary screening

of abstracts and titles to find potentially relevant papers, a comprehensive evaluation of full-text publications is conducted to determine which are most relevant to the goals of the review.

- **Categorization and Analysis:**

The study employs a systematic way to classify data on cancer immunotherapy, ranging from scientific developments to clinical applications. The creation, characterization, and therapeutic usefulness of different immunotherapy modalities are highlighted by analytical categories. Carefully examined are the ingredients, production methods, and clinical results of immune checkpoint inhibitors, CAR T-cell therapy, and cancer vaccines. The review is organized around these topics in an effort to provide readers a thorough grasp of the most current developments in cancer immunotherapy and how they affect clinical practice.



RESULTS

- **Immunotherapies:**

Among the many therapeutic options available for treating various malignancies, including solid and haematological tumors, immunotherapy has emerged as an advanced treatment method.

Immunotherapies aim to combat cancer by using the patient's own immune system, opening the door to more specialized and potent treatments. For patients with various malignancies, cancer

immunotherapy is a viable treatment option since it has comparatively less adverse effects than chemotherapy8. Monoclonal antibodies (mAbs), mRNA vaccines, immune checkpoint inhibitors, and adoptive cell transfer in the form of chimeric antigen receptor (CAR)-T cell treatments are among the immunotherapy medications available today (Dede et al. 2023).

Depending on the immune response, cancer immunotherapy is categorized as either active or passive. Agents such as lymphocytes, cytokines, or mAbs that boost the body's natural anti-tumor response are used in passive immunotherapy. Vaccination, non-specific immunomodulation, and immune system activation by selective antigen receptor targeting to tumour cells are examples of active immunotherapy techniques (Dede et al. 2023). Limiting factors, such as intertumoral heterogeneity, inadequate production and function of tumor-specific CD8 T-cells, lack of appropriate neoantigens with defective processing, and antigen presentation, inhibit the activation of tumor-specific immune responses, in contrast to the successful immunotherapy approaches11. T-cell immune checkpoint pathways are mostly linked to immune response resistance mechanisms. Therefore, reducing immune response evasion may be achieved by examining novel immunological checkpoints and molecular pathways. Finding tactics that will improve T-cell continuity and proliferation, decrease immunosuppression, and stop T-cell depletion is essential to improving the response to immunotherapeutic (Peng et al. 2019).

- **Immune Checkpoint Inhibitor Therapy**

One of the most promising classes of cancer immunotherapy is immune checkpoint inhibitors (ICI). Over the last ten years, the FDA has approved many medications for more than nine different forms of cancer (Dobosz and Dzieciątkowski 2019). The foundation of ICI treatment is the idea that T cells have negative regulatory signals that have been preserved throughout evolution, serving as "checkpoints" to control activation (Waldman, Fritz, and Lenardo 2020). Programmed cell death 1 (PD-1) and inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA4) are upregulated by T lymphocytes early after activation. These molecules subsequently bind to co-stimulatory ligands B7-1, B7-2, and PD-L1 or PD-L2, respectively (Hui et al. 2017). Tumour cells, regulatory T cells (Trigs), myeloid cells, and antigen-presenting cells (APCs) deliver ligands that decrease the activation of cytotoxic T cells, which leads to immune suppression and tumour progression. Immune checkpoint inhibitor therapy releases inhibition, allowing primed and activated cytotoxic T cells to attack and kill cancer cells (Kamp horst et al. 2017). Many malignancies that have proven resistant to therapy have been successfully treated with ICI. Patients who had previously had poor prognoses after receiving traditional cancer treatments including chemotherapy, radiation therapy, and targeted therapy have shown significant improvement because to ICI. Long-lasting immune memory may be seen in individuals who react to ICI, according to durable responses.

The first immune checkpoint inhibitor (ICI) to get FDA approval was ipilimumab, a therapeutic anti-CTLA4 human IgG1 monoclonal antibody that has been used to treat a variety of illnesses (Jenkins, Barbie, and Flaherty 2018) (Lenz et al. 2022). ICIs have had mixed results, with some being effective and others failing. Tremelimumab, a further anti-CTLA antibody of the IgG2 isotype, was not able to achieve its main goal in late-stage clinical studies for metastatic advanced melanoma. It's unknown why tremelimumab and imipilimumab seem to have differing effects on antibody-dependent cell-mediated cytotoxicity (ADCC). These antibodies may influence the clinical outcome of tumor-infiltrating regulatory T cells by mediating their depletion via ADCC (Sharma, Vacher, and Allison 2019). Compared to standard-of-care chemotherapy, Pembro has shown a significant increase in the overall response rate (ORR) in patients with melanoma and NSCLC. ICI has replaced chemotherapy as the first line of treatment for melanoma (nivolumab/pembro) and non-small cell lung cancer (atezolizumab) in select patients (Horn et al. 2018). Anti-CTLA4 + anti-PD-1 combination treatment has shown a markedly enhanced ORR of 58% for

metastatic melanoma (Larkin et al. 2015). Nonetheless, heightened toxicity after concurrent therapy is frequent and continues to be a problem.

Improved responses to pembro have been linked to increased PD-L1 expression, and in certain cancer subtypes, the degree of PD-L1 expression is used as a biomarker to direct the indication for ICI (Chen et al. 2019) (Cohen et al. 2019). It is important to highlight the kind of scoring method that is used, whether it is a composite score, tumor-derived PD-L1, or TME-derived PD-L1. Treatments using anti-PD-L1 antibodies have also been shown to be successful in treating several cancer types. Avelumab and durvalumab are licenced for the treatment of many kinds of solid tumour malignancies (D'Angelo et al. 2021) (Motzer et al. 2019). Atezolizumab was the first anti-PD-L1 ICI to be approved for the treatment of urothelial carcinoma. Another biomarker for anti-PD-L1 ICI therapy indication has been tumour PD-L1 expression.

Defective DNA mismatch repair (dMMR) proteins cause microsatellite instability in cancer. Microsatellite instability at high levels (MSI-H) has been linked to significantly better prognoses in a number of cancer subtypes, including colorectal and ovarian cancer (CRC) (Fraune et al. 2020). Pembro was the first medication licenced in the disease-agnostic scenario based only on the presence of MSI-H, independent of the cancer subtype, because to the significantly better results seen with MSI-H and ICI [45]. In dMMR rectal cancer, a recent clinical trial using the anti-PD-1 ICI dostarlimab demonstrated a 100% clinical ORR and no recurrence to date (Cercek et al. 2022).

Only 20 to 30 percent of patients get a clinical response to ICI, despite the fact that responders see tremendous improvements from it. Therefore, a thorough knowledge of additional checkpoint mechanisms and how they could be addressed is essential to treating the majority of patients. The CD226-PVR pathway controls T-cell immunity via the T-cell immunoreceptor with immunoglobulin (Ig) and ITIM domains (TIGIT), an inhibitory protein found on CD8+ and CD4+ T cells, Trigs, and natural killer (NK) cells. Roughly twenty monoclonal antibodies that specifically target TIGIT have been created and are intended to be utilised as single agents or in combination with anti-PD-1 or anti-PD-L1 drugs (Chiang and Mellman 2022). Anti-TIGIT IgG1 antibody tiragolumab, when paired with atezolizumab, demonstrated better clinical effectiveness in non-small cell lung cancer (NSCLC) compared to atezo plus placebo. It is now being studied in many Phase III studies for solid tumours (Cho et al. 2022). Early phase trials have also shown encouraging therapeutic action for two other anti-TIGIT antibodies, vibostolimab and etigilimab (Niu et al. 2022) (Mettu et al. 2022).

- **CAR T-Cell Therapy**

Adoptive cellular therapy (ACT) used to include genetically modified T-cell receptor (TCR) treatments, TIL infusion, and CAR-modified T cells (Rosenberg et al. 2008). NK, CAR-NK, and CAR-M cells are being studied as potential therapies, although none have been FDA-approved. The most successful ACT to yet is CAR T-cell therapy (CART), which is utilised internationally for a variety of hematologic malignancies and has multiple FDA-approved uses. Here, we discuss CART's successes, issues, and research opportunities.

Eshhar et al. first detailed the process of creating CAR T cells, which included attaching a CD3ζ signalling chain to a mouse single-chain variable fragment antibody domain (svFC) and then inserting it onto a human T cell. First-generation CARs activated T cells without HLA when supplied a target antigen identified by the svFC (Peterson, Denlinger, and Yang 2022). CAR T-cell proliferation, persistence, and pre-clinical efficacy enhanced in 2011 when costimulatory domains (usually CD28 or 4-1BB) were added to CAR designs (Van Der Stegen, Hamieh, and Sadelain 2015). These "2nd generation" CAR designs have

shown unprecedented clinical success, notably against BCMA-expressing multiple myeloma and B-cell maturation antigen.

Diffuse large B-cell lymphoma (DLBCL), the most common NHL subtype, responds well to CART. Relapsed/refractory DLBCL results were disappointing. Traditionally, patients who were inappropriate for autologous stem cell transplantation or experienced recurrence after the transplant had a 20–30% ORR to the next line of therapy and a median OS of six months (Crump et al. 2017). For autologous anti-CD19 CART (CAR19) in R/R DLBCL patients, ZUMA-1 (axicabtagene ciloleucel) and JULIET (tisagenlecleucel) were essential studies. Apheresis was utilised to extract autologous mononuclear cells, process them to identify T cells, modify them with an anti-CD19 scFV, multiply them, and reintroduce them into the patient. Most patients had considerable post-infusion growth for tisa-cel (4-1BB co-stimulatory domain) and axical (CD28 costimulatory domain) (Schuster et al. 2019). CAR19 had a 40–54% CR rate, 54–82% ORR, and a median OS of years. Real-world trials showed that most patients achieved a CR and 30–40% maintained a durable remission for five years or more after receiving a CAR infusion (Schuster et al. 2021). CAR19 is the standard of therapy for R/R aggressive NHL after two or more lines of treatment, but new findings support shifting CART to the second line, for which axical was just FDA-approved (Locke et al. 2022).

By targeting BCMA, CART has showed potential in treating R/R Multiple Myeloma. In 2021, idecabtegene vicleucel was authorised after a phase 2 study showed 73% ORR and 33% CR in severely pretreated, relapsed, refractory patients (Munshi et al. 2021). Cleatacabtagene autoleucel, a second anti-BCMA CART, responded well in R/R MM patients with substantial pretreatment, with a 97% ORR, 67% CR rate, and 77% durable response at 1 year (Jacobson, Westin, et al. 2020). In retrospective analysis, non-CART patients had considerably lower outcomes than CART patients (Costa et al. 2022). Clinical trials are needed to determine the ideal CART timing for MM.

Two anti-BMCM CART and four CAR19 drugs are FDA-approved. Though hurdles remain, CART has transformed hematologic cancer therapy. Relapse and treatment failure occur in most CART patients (Hunter, Rogalski, and Jacobson 2019). Children have showed long-lasting remissions from acute lymphoblastic leukaemia (all), however most adult patients require an allogeneic stem cell transplant following CAR19 due to high recurrence rates (B. D. Shah et al. 2021). CART resistance mechanisms must be studied to overcome these concerns. CART failure may lead to initial resistance or response followed by relapse. These two forms of failure have different causes, although they may not be mutually exclusive. The major reasons of cart failure include tumour or disease-intrinsic factors, CAR T-cell product-specific processes, and CAR T-cell/host interactions. Target antigen loss or mutation (e.g., CD19 extracellular epitope on leukemic/lymphoma cells) causes tumour intrinsic CAR T-cell failure [77,78]. CD19 (-) leukaemia recurs in 10–20% of ALL patients (Maude et al. 2018). Alternative antigen and multi-antigen treatments are being explored to counteract antigen loss. Shah et al. found that anti-CD22-directed CAR T-cell treatment may achieve 70% ALL CR rates after CAR19 failed (N. N. Shah et al. 2020). Anti-CD22 clinical trials have also helped NHL after CAR19 failure (Baird et al. 2021). Despite promising outcomes, CD22 or CD20 antigen reduction may be a drawback. Thus, various clinical trials integrating several antigen targets (such as CD19/22) on a single CAR are underway. The OSUCCC will soon start a tri-specific CD19/20/22 CART research (Schneider et al. 2021).

The CAR T-cell product's intrinsic flaws limit growth and function. Transduction efficiency, phenotype, and CART viability impact clinical outcomes. Poor growth conditions, manufacturing faults, low-quality donor T cells from earlier therapy, and/or high disease burden during apheresis may reduce production (Jacobson, Hunter, et al. 2020). Both patient state and manufacturing process must be adjusted to

address CART product failure. Cytoreduction may affect product quality, hence cell product collection before and after bridging therapy must be studied. Point-of-care production, unique culture conditions, and variable culture duration are three cutting-edge CAR T-cell manufacturing methods. Point-of-care manufacturing accelerates vein-to-vein and may improve treatment results (Jackson et al. 2020). T stem-cell-like memory populations have risen in recent research employing IL7 and IL15 for CART culture growth instead of IL-2 using FDA-approved materials and a shorter 8-day production time, which may enhance expansion and efficacy. The 2-day expansion-free commercial manufacturing of 4-1BB CAR19 has shown positive results (Flinn et al. 2021). Instead of ex vivo, this faster method boosted stemness and proliferative ability by expanding CAR T cells in people [87,88].

The injected CAR T-cell product and TME interact to cause tumour, host, and CAR T-cell interactions. Host systemic inflammation and tumour burden may affect immunosuppressive TME-CAR T cell proliferation and exhaustion (Locke et al. 2020). Retrospective studies have identified extranodal disease sites ≥2, elevated inflammatory markers (lactate dehydrogenase and C-reactive protein), and high metabolic tumour volume at treatment initiation as risk factors for CAR T-cell failure (Vercellino et al. 2020). Jain et al. reported that a poorer CAR19 response was related with more protumoral tumor-associated macrophage (TAM) markers, TME PD-L1 expression, and MDSC circulation (Jain et al. 2021). Enhanced TME and tumour heterogeneity are regarded to be the major reasons CART fails for solid cancers. New conditioning, bridging, and radiation regimens before CART are being studied to overcome TME-mediated CART suppression (Gauthier et al. 2021).

CAR T-cell therapy is very effective in hematologic malignancies that express CD19 and BCMA, but it is ineffective in most patients and most other solid and hematologic malignancies. This requires further foundational research into cutting-edge CART cell engineering approaches to improve tumour detection, TME infiltration, and anti-cancer activity.

- **Tumor-infiltrating immune cells and their associations with immunotherapies**
- **T lymphocytes:**

Tumor immunology relies heavily on T cells, especially cytotoxic T lymphocytes (CTLs), which trigger antitumor responses by binding to major histocompatibility complex (MHC) molecules and presenting tumor antigens. Nonetheless, T cell activity is often impaired in the tumor microenvironment (TME) due to fatigue or immunosuppressive factor-induced malfunction. Notably, poor results are associated with T cell fatigue, which is often seen in human malignancies and is characterised by increased expression of inhibitory molecules such PD-1. Thommen et al. (2018) showed that in patients with non-small cell lung cancer, TILs with high PD-1 expression predict positive responses to anti-PD-1 therapy (Thommen et al. 2018). Furthermore, CD4 T cells—which include regulatory T cells (Trigs) and T helper (TH) cells—have important but different functions in tumor immunity, with Trigs inhibiting T cell activity and TH cells supporting antitumor responses (PM Forde 2018). The complex interactions between immune checkpoints and T cell subsets highlight the potential use of immune checkpoint inhibitors (ICIs), such as anti-PD-1 and anti-CTLA-4 antibodies, in the treatment of cancer. These results highlight how crucial it is to address T cell malfunction in order to improve cancer immunotherapy.

- **B lymphocytes**

Adaptive immune system humoral immunity includes B lymphocytes. In response to tumours or infections, B cells might become plasma or memory B cells. Immunoglobulins (Igs), or antibodies, may bind and neutralise target antigens. To activate B cells, antigens engage with the B-cell receptor (BCR), a membrane-bound form of Ig (mIg) that provides B cells antigen specificity. Because the Ig gene

segments are randomly rearranged, each B-cell has a diverse BCR repertoire, resulting in its unique BCR (Sautès-Fridman et al. 2019). BCRs have several antigen specificities. Class-switch recombination and somatic hypermutation in the germinal centre may change a BCR and make optimised antibodies against target antigens when it encounters an antigen.

Due to humoral and cellular immunity, B cells vary in anticancer immunity.127 Tumor-infiltrating B cells (TIBs) accelerate tumour growth by preventing T-cell-mediated immune responses, secreting soluble mediators that stimulate myeloid cells' proangiogenic and protumorigenic activities, or generating compounds that help cancer cells communicate.128.129.130 Contrary to their propensity to induce cancer, B cells may enhance patient outcomes by promoting antitumor immunity. APCs that boost cytolytic T-cell responses may explain why CD20+ TIBs are favourably linked with outcome in NSCLC and ovarian cancer patients.131,132 In particular, Cabrita et al. discovered that TLS formation and the presence of CD8+ T cells and CD20+ B cells in tumours predicted immune checkpoint inhibitor (ICI) clinical outcomes and improved metastatic melanomas survival (Cabrita et al. 2020). B cells seem to be involved in immunotherapy responses. ICIs activated B and T follicular helper cells in high mutation load triple-negative breast cancer mice models, according to Hollern et al (Hollern et al. 2019). Then, activated B cells might secrete antibodies and activate T cells by antigen presentation to fight cancer.134 Clinical studies stress the importance of B cells and TLSs in cancer immunotherapy, supporting these mouse findings. Petitprez et al. found that soft-tissue sarcoma patients with TLSs which included B cells and other immune cells had improved survival and a high response rate to PD-1 inhibition (Petitprez et al. 2020). Helmink et al. consistently found T cells and CD20+ B cells in TLSs of metastatic renal cell cancer (RCC) and metastatic melanoma patients who responded to ICI medication (Helmink et al. 2020) They also found BCR variety and clonal growth in responders, shedding light on TLSs and B cells' crucial roles in cancer immunotherapy.

These results show that B cells regulate the immune system against tumours and imply that TLSs and B cells may be useful in cancer therapy. More study is needed to understand B-cell-mediated immunotherapies responsive mechanisms.

- **NK cells**

Important elements of innate immunity include natural killer (NK) cells, which may carry out cytotoxic actions without being specific for the major histocompatibility complex (MHC). By use of cytolytic granules, they eradicate tumour cells directly; by means of proinflammatory cytokines and chemokines, they cooperate with other immune cells. A balance between activating and inhibiting receptors on the surface of NK cells controls their activity. While activating receptors detect signs of cellular stress linked to viral infection or cancer, inhibitory receptors interact with MHC class I molecules on normal cells. On the other hand, NK cell function may be impaired inside the tumour microenvironment (TME), which may result in altered cytokine expression and decreased cytotoxic efficacy. Research such as that conducted by Böttcher et al. has brought attention to the interaction between NK cells and the TME, pointing to possible therapeutic targets to improve NK cell activity and counteract tumor-induced immune evasion (Böttcher et al. 2018).

Numerous NK-based immunotherapies have been studied, such as chimeric antigen receptor (CAR)-NK cell treatments, cytokine therapies, adoptive transfer of autologous NK cells, and monoclonal antibody (mAb)-based therapies. By directly infusing activated or modified NK cells, administering cytokines to improve NK cell function, or using monoclonal antibodies to target inhibitory receptors on NK cells, these strategies seek to increase NK cell activity. For example, blocking inhibitory receptors like CD94/NKG2A

heterodimers or killer immunoglobulin receptors (KIRs) has shown potential to improve NK cell-mediated antitumor responses. Additionally, preclinical models have shown the effectiveness of techniques that take advantage of activating receptors, including NKG2D. Another way to increase NK cell cytotoxicity against tumours is by the creation of new antibodies that target stress-induced compounds that are recognised by activating receptors, such as MICA and MICB (De Andrade et al. 2018). All things considered, NK cell treatment presents a promising new direction for cancer immunotherapy, which calls for further investigation into the field and clinical testing.

- **Cancer Vaccines**

Tumor-specific or tumor-associated antigens (TAA) are presented to the immune system by cancer vaccines, which play a crucial role in boosting T-cell and immunological responses (Liu et al. 2022). However, since many tumor-specific antigens (TAAs) are also expressed in healthy tissues, developing cancer vaccines that target TAAs presents difficulties because of the possibility of autoreactive immune responses. Neoantigens provide a viable path for the production of cancer vaccines as they are the result of mutations in carcinogenic genes and are not present in normal tissues. The discovery of neoantigens, which are particular to tumour cells and act as targets for the immune system, has been made easier by next-generation sequencing (Liu et al. 2022).

The four main platforms used by cancer vaccines are cells, viruses, peptides, and nucleic acids (Liu et al. 2022). For instance, the overexpressed TAA prostatic acid phosphatase is the target of sipuleucel-T (Provenge), the first FDA-approved cancer vaccine for metastatic castration-resistant prostate cancer, which stimulates an immune response unique to prostate cancer. Furthermore, clinical research has shown the potential of oncolytic viral immunotherapy, which employs vectors such as adenoviruses and herpes simplex viruses (Liu et al. 2022). A first-generation recombinant herpes simplex virus vector called T-VEC (Imlygic) has shown promise in treating recurrent melanoma.

Strong immune responses are elicited by peptide-based vaccinations, which include chemical and biosynthetic formulations of cancer antigens (Spira et al. 2021). Strong T-cell responses are also elicited by nucleic acid vaccinations, such as DNA and mRNA vaccines. Numerous cervical cancer studies have shown the effectiveness of DNA vaccines encoding entire tumour antigens (Liu et al. 2022). Customised immunisations are also made possible by mRNA vaccines expressing tumour neoantigens, immunostimulants, and TAAs. Memory neoantigen-specific T lymphocytes with long-term persistence have been shown to be generated using customised mRNA vaccines, such as NeoVax for melanoma patients (Hu et al. 2021). Analogous research in patients with glioblastoma has shown encouraging antitumor outcomes.

Due to its safety, stability, and ease of use, DNA vaccination has become a preferred cancer immunotherapy. DNA immunisations have little negative effects, according to research. DNA vaccines may be administered repeatedly for long-term protection and are inexpensive. DNA vaccines are intriguing, but tumor-antigen immunological tolerance makes antigen-specific cellular immune responses problematic. Researchers have investigated many novel methods to increase DNA vaccine immunogenicity against self-antigen-producing tumours. These include coding xenogeneic antigens or combining antigens with T-cell-stimulating molecules (fusion proteins with the CTLA4 ligand-binding domain covalently attached to an Ag are strong immunogens) (Peterson, Denlinger, and Yang 2022). or immunomodulatory drugs, priming with DNA vectors and boosting with viral vectors, or associative recognition.

DISCUSSION

Particular attention is paid to immune checkpoint inhibitors, CAR T-cell therapy, and cancer vaccines in this thorough study, which offers a thorough summary of current developments in cancer immunotherapy. Patients suffering from a variety of cancers now have fresh hope because to treatment techniques that use the immune system's capacity to target and eliminate cancer cells.

By focusing on important regulatory mechanisms that hinder the immune system's ability to fight cancers, immune checkpoint inhibitors (ICI) have completely changed the way cancer is treated (Dobosz and Dzieciątkowski, 2019). According to Jenkins, Barbie, and Flaherty (2018), medications that target cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed cell death 1 (PD-1) have shown impressive efficacy in treating a variety of cancer types, resulting in long-lasting responses and higher survival rates. The study emphasizes the value of combination treatments, which have shown improved effectiveness in metastatic melanoma (Larkin et al., 2015). One such combination therapy is anti-CTLA4 + anti-PD-1. It does, however, also recognize the drawbacks of ICI treatment, such as increased toxicity and patient variability in response rates.

Another potential method in cancer immunotherapy is CAR T-cell treatment, especially for hematologic malignancies (Rosenberg et al., 2008). CAR T-cell therapy has produced remarkable clinical results, including high response rates and long-lasting remissions in patients with relapsed/refractory B-cell malignancies, by genetically modifying patients' T cells to express chimeric antigen receptors (CARs) that target tumor-specific antigens (Schuster et al., 2019). From first-generation CARs to more advanced second-generation CARs with costimulatory domains, which have increased CAR T cell proliferation and persistence, the review explores the development of CAR T-cell design (Van Der Stegen, Hamieh, and Sadelain, 2015).

Furthermore, the paper explores the function of immune cells that penetrate tumors, such as natural killer (NK) cells, T lymphocytes, and B lymphocytes, in cancer immunotherapy. In order to improve the effectiveness of immunotherapy, it emphasizes the significance of conquering immune evasion mechanisms inside the tumor microenvironment (TME) (Böttcher et al., 2018). Immunocheckpoint blocking is one strategy that targets T cell fatigue and has the potential to boost anticancer immune responses again (Thommen et al., 2018). The review also emphasizes the dual function of B lymphocytes in cancer immunity, as they may either stimulate the development of tumors or improve immunity against cancer by forming tertiary lymphoid structures (TLSs) (Cabrita et al., 2020).

The development of cancer vaccines that target tumor-specific or tumor-associated antigens (TAA) is covered in the review's last section (Liu et al., 2022). The identification of neoantigens opens up new possibilities for tailored cancer immunotherapy, yet conventional cancer vaccines are hindered by possible autoimmune reactions. The review describes several vaccination platforms such as viruses, peptides, cells, and nucleic acids and describes the clinical effectiveness of oncolytic viral immunotherapy and sipuleucel-T in certain cancer types.

CONCLUSION

The thorough analysis concludes by highlighting the revolutionary role that cancer immunotherapy plays in the management of hematologic and solid malignancies. Cancer vaccines, CAR T-cell therapy, and immune checkpoint inhibitors are examples of cutting-edge strategies that use the body's immune system to target and destroy cancer cells. When compared to conventional therapy, these modalities have shown considerable therapeutic advantages, such as longer-lasting responses, higher survival rates, and fewer side effects.

Notwithstanding the noteworthy advancements in cancer immunotherapy, a number of limitations and challenges persist. The emergence of resistance mechanisms, varying response rates across patients, and immune-related side effects provide formidable challenges to the broad implementation of these treatments. Furthermore, many patients are unable to obtain tailored therapies like CAR T-cell therapy due to their high cost and logistical challenges. Furthermore, there are significant obstacles in the way of attaining consistent and long-lasting responses across various cancer types due to the heterogeneity of tumors and the tumor microenvironment.

It is recommended that future research endeavors concentrate on resolving these constraints and propelling the domain of cancer immunotherapy forward. Immune-modulating drugs, biomarker-driven strategies, and innovative combination medicines show promise in improving treatment effectiveness and overcoming resistance mechanisms. Moreover, the creation of novel manufacturing processes and delivery systems may simplify the preparation and distribution of cellular treatments, increasing their accessibility for a larger range of patients. Furthermore, finding new targets and refining therapeutic approaches will need sustained funding for translational research and preclinical models. In order to improve outcomes for cancer patients globally and expedite the translation of research discoveries into clinical practice, collaborative efforts including academics, industry, and regulatory authorities will be crucial. Through tackling these obstacles and seizing fresh chances, the domain of cancer immunotherapy is well-positioned to sustain its progress and influence in the next years.

REFERENCES

1. De Andrade, Lucas Ferrari et al. 2018. "Antibody-Mediated Inhibition of MICA and MICB Shedding Promotes NK Cell-Driven Tumor Immunity." *Science* 359(6383): 1537–42. https://www.science.org/doi/10.1126/science.aao0505 (February 23, 2024).
2. Baird, John H. et al. 2021. "CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR–Refractory Large B-Cell Lymphoma." *Blood* 137(17): 2321–25.
3. Böttcher, Jan P. et al. 2018. "NK Cells Stimulate Recruitment of CDC1 into the Tumor Microenvironment Promoting Cancer Immune Control." *Cell* 172(5): 1022-1037.e14.
4. Cabrita, Rita et al. 2020. "Tertiary Lymphoid Structures Improve Immunotherapy and Survival in Melanoma." *Nature 2020 577:7791* 577(7791): 561–65. https://www.nature.com/articles/s41586-019-1914-8 (February 23, 2024).
5. Cercek, Andrea et al. 2022. "PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer." *New England Journal of Medicine* 386(25): 2363–76.
6. Chen, Robert et al. 2019. "Pembrolizumab in Relapsed or Refractory Hodgkin Lymphoma: 2-Year Follow-up of KEYNOTE-087." *Blood* 134(14): 1144–53.
7. Chiang, Eugene Y., and Ira Mellman. 2022. "TIGIT-CD226-PVR Axis: Advancing Immune Checkpoint Blockade for Cancer Immunotherapy." *Journal for ImmunoTherapy of Cancer* 10(4).
8. Cho, Byoung Chul et al. 2022. "Tiragolumab plus Atezolizumab versus Placebo plus Atezolizumab as a First-Line Treatment for PD-L1-Selected Non-Small-Cell Lung Cancer (CITYSCAPE): Primary and Follow-up Analyses of a Randomised, Double-Blind, Phase 2 Study." *The Lancet Oncology* 23(6): 781–92.
9. Cohen, Ezra E.W. et al. 2019. "Pembrolizumab versus Methotrexate, Docetaxel, or Cetuximab for Recurrent or Metastatic Head-and-Neck Squamous Cell Carcinoma (KEYNOTE-040): A Randomised, Open-Label, Phase 3 Study." *The Lancet* 393(10167): 156–67.
10. Costa, Luciano J. et al. 2022. "Comparison of Cilta-Cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma." *Clinical Lymphoma, Myeloma and Leukemia* 22(5): 326–35.

11. Crump, Michael et al. 2017. "Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from the International SCHOLAR-1 Study." *Blood* 130(16): 1800–1808.
12. D'Angelo, Sandra P. et al. 2021. "First-Line Avelumab in a Cohort of 116 Patients with Metastatic Merkel Cell Carcinoma (JAVELIN Merkel 200): Primary and Biomarker Analyses of a Phase II Study." *Journal for ImmunoTherapy of Cancer* 9(7).
13. Dede, Zeynep, Kader Tumer, Tugce Kan, and Burcu Yucel. 2023. "Current Advances and Future Prospects in Cancer Immunotherapeutics." *Medeniyet Medical Journal* 38(1): 88. /pmc/articles/PMC10064104/ (February 22, 2024).
14. Dobosz, Paula, and Tomasz Dzieciątkowski. 2019. "The Intriguing History of Cancer Immunotherapy." *Frontiers in Immunology* 10.
15. Ferlay, Jacques et al. 2021. "Cancer Statistics for the Year 2020: An Overview." *International Journal of Cancer* 149(4): 778–89. https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.33588 (February 22, 2024).
16. Flinn, Ian W. et al. 2021. "A First-in-Human Study of YTB323, a Novel, Autologous CD19-Directed CAR-T Cell Therapy Manufactured Using the Novel T-Charge TM Platform, for the Treatment of Patients (Pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)." *Blood* 138(Supplement 1): 740–740.
17. Fraune, Christoph et al. 2020. "High Homogeneity of MMR Deficiency in Ovarian Cancer." *Gynecologic Oncology* 156(3): 669–75.
18. Gauthier, Jordan et al. 2021. "Factors Associated with Outcomes after a Second CD19-Targeted CAR T-Cell Infusion for Refractory B-Cell Malignancies." *Blood* 137(3): 323–35.
19. Helmink, Beth A. et al. 2020. "B Cells and Tertiary Lymphoid Structures Promote Immunotherapy Response." *Nature 2020 577:7791* 577(7791): 549–55. https://www.nature.com/articles/s41586-019-1922-8 (February 23, 2024).
20. Hollern, Daniel P. et al. 2019. "B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer." *Cell* 179(5): 1191-1206.e21. https://doi.org/10.1016/j.cell.2019.10.028.
21. Horn, Leora et al. 2018. "First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer." *New England Journal of Medicine* 379(23): 2220–29.
22. Hu, Zhuting et al. 2021. "Personal Neoantigen Vaccines Induce Persistent Memory T Cell Responses and Epitope Spreading in Patients with Melanoma." *Nature Medicine 2021 27:3* 27(3): 515–25. https://www.nature.com/articles/s41591-020-01206-4 (February 23, 2024).
23. Hui, Enfu et al. 2017. "T Cell Costimulatory Receptor CD28 Is a Primary Target for PD-1-Mediated Inhibition." *Science* 355(6332): 1428–33.
24. Hunter, Bradley D., Michael Rogalski, and Caron A. Jacobson. 2019. "Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphomas: Efficacy, Toxicity, and Comparative Chimeric Antigen Receptor Products." *Expert Opinion on Biological Therapy* 19(11): 1157–64.
25. Jackson, Zachary et al. 2020. "Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-Hodgkin Lymphoma." *Frontiers in Immunology* 11.
26. Jacobson, Caron A., Jason R. Westin, et al. 2020. "Abstract CT055: Phase 1/2 Primary Analysis of ZUMA-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination With Atezolizumab (Atezo) for the Treatment of Patients (Pts) with Refractory Diffuse Large B Cell Lymphoma (DLBCL)." *Cancer Research* 80(16_Supplement): CT055–CT055.
27. Jacobson, Caron A., Bradley D. Hunter, et al. 2020. "Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity." *Journal of Clinical*

Oncology 38(27): 3095–3106.
28. Jain, Michael D. et al. 2021. "Tumor Interferon Signaling and Suppressive Myeloid Cells Are Associated with CAR T-Cell Failure in Large B-Cell Lymphoma." *Blood* 137(19): 2621–33.
29. Jenkins, Russell W., David A. Barbie, and Keith T. Flaherty. 2018. "Mechanisms of Resistance to Immune Checkpoint Inhibitors." *British Journal of Cancer* 118(1): 9–16.
30. Kamphorst, Alice O. et al. 2017. "Rescue of Exhausted CD8 T Cells by PD-1-Targeted Therapies Is CD28-Dependent." *Science* 355(6332): 1423–27.
31. Larkin, James et al. 2015. "Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma." *New England Journal of Medicine* 373(1): 23–34.
32. Lenz, Heinz Josef et al. 2022. "First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/ Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study." *Journal of Clinical Oncology* 40(2): 161–70.
33. Liu, Jian et al. 2022. "Cancer Vaccines as Promising Immuno-Therapeutics: Platforms and Current Progress." *Journal of Hematology & Oncology 2022 15:1* 15(1): 1–26. https://link.springer.com/articles/10.1186/s13045-022-01247-x (February 23, 2024).
34. Locke, Frederick L. et al. 2020. "Tumor Burden, Inflammation, and Product Attributes Determine Outcomes of Axicabtagene Ciloleucel in Large B-Cell Lymphoma." *Blood Advances* 4(19): 4898–4911.
35. ———. 2022. "Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma." *New England Journal of Medicine* 386(7): 640–54.
36. Maude, Shannon L. et al. 2018. "Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia." *New England Journal of Medicine* 378(5): 439–48.
37. Mettu, Niharika B. et al. 2022. "A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors." *Clinical Cancer Research* 28(5): 882–92.
38. Miller, Kimberly D. et al. 2022. "Cancer Treatment and Survivorship Statistics, 2022." *CA: A Cancer Journal for Clinicians* 72(5): 409–36. https://onlinelibrary.wiley.com/doi/full/10.3322/caac.21731 (February 22, 2024).
39. Motzer, Robert J. et al. 2019. "Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma." *New England Journal of Medicine* 380(12): 1103–15.
40. Munshi, Nikhil C. et al. 2021. "Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma." *New England Journal of Medicine* 384(8): 705–16.
41. Niu, J. et al. 2022. "First-in-Human Phase 1 Study of the Anti-TIGIT Antibody Vibostolimab as Monotherapy or with Pembrolizumab for Advanced Solid Tumors, Including Non-Small-Cell Lung Cancer☆." *Annals of Oncology* 33(2): 169–80.
42. Peng, Miao et al. 2019. "Neoantigen Vaccine: An Emerging Tumor Immunotherapy." *Molecular Cancer 2019 18:1* 18(1): 1–14. https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-019-1055-6 (February 22, 2024).
43. Peterson, Chelsea, Nathan Denlinger, and Yiping Yang. 2022. "Recent Advances and Challenges in Cancer Immunotherapy." *Cancers 2022, Vol. 14, Page 3972* 14(16): 3972. https://www.mdpi.com/2072-6694/14/16/3972/htm (February 22, 2024).
44. Petitprez, Florent et al. 2020. "B Cells Are Associated with Survival and Immunotherapy Response in Sarcoma." *Nature 2020 577:7791* 577(7791): 556–60. https://www.nature.com/articles/s41586-019-1906-8 (February 23, 2024).
45. PM Forde, JE Chaft, DM Pardoll. 2018. "Neoadjuvant PD-1 Blockade in Resectable Lung Cancer." *N. Engl. J. Med.* 379: e14.

46. Rosenberg, Steven A. et al. 2008. "Adoptive Cell Transfer: A Clinical Path to Effective Cancer Immunotherapy." *Nature Reviews Cancer* 8(4): 299–308.
47. Sautès-Fridman, Catherine, Florent Petitprez, Julien Calderaro, and Wolf Herman Fridman. 2019. "Tertiary Lymphoid Structures in the Era of Cancer Immunotherapy." *Nature Reviews Cancer 2019 19:6* 19(6): 307–25. https://www.nature.com/articles/s41568-019-0144-6 (February 23, 2024).
48. Schneider, Dina et al. 2021. "Trispecific CD19-CD20-CD22-Targeting DuoCAR-T Cells Eliminate Antigen-Heterogeneous B Cell Tumors in Preclinical Models." *Science Translational Medicine* 13(586).
49. Schuster, Stephen J. et al. 2019. "Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma." *New England Journal of Medicine* 380(1): 45–56.
50. ———. 2021. "Long-Term Clinical Outcomes of Tisagenlecleucel in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (JULIET): A Multicentre, Open-Label, Single-Arm, Phase 2 Study." *The Lancet Oncology* 22(10): 1403–15.
51. Shah, Bijal D. et al. 2021. "KTE-X19 for Relapsed or Refractory Adult B-Cell Acute Lymphoblastic Leukaemia: Phase 2 Results of the Single-Arm, Open-Label, Multicentre ZUMA-3 Study." *The Lancet* 398(10299): 491–502.
52. Shah, Nirali N. et al. 2020. "CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results from a Phase I Anti-CD22 CAR T-Cell Trial." *Journal of Clinical Oncology* 38(17): 1938–50.
53. Sharma, Naveen, Jean Vacher, and James P. Allison. 2019. "TLR1/2 Ligand Enhances Antitumor Efficacy of CTLA-4 Blockade by Increasing Intratumoral Treg Depletion." *Proceedings of the National Academy of Sciences of the United States of America* 116(21): 10453–62.
54. Spira, Alexander et al. 2021. "Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies." *Targeted Oncology* 16(4): 461–69. https://link.springer.com/article/10.1007/s11523-021-00813-6 (February 23, 2024).
55. Van Der Stegen, Sjoukje J.C., Mohamad Hamieh, and Michel Sadelain. 2015. "The Pharmacology of Second-Generation Chimeric Antigen Receptors." *Nature Reviews Drug Discovery* 14(7): 499–509.
56. Thommen, Daniela S. et al. 2018. "A Transcriptionally and Functionally Distinct PD-1+ CD8+ T Cell Pool with Predictive Potential in Non-Small-Cell Lung Cancer Treated with PD-1 Blockade." *Nature Medicine 2018 24:7* 24(7): 994–1004. https://www.nature.com/articles/s41591-018-0057-z (February 23, 2024).
57. Vercellino, Laetitia et al. 2020. "Predictive Factors of Early Progression after CAR T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma." *Blood Advances* 4(22): 5607–15.
58. Waldman, Alex D., Jill M. Fritz, and Michael J. Lenardo. 2020. "A Guide to Cancer Immunotherapy: From T Cell Basic Science to Clinical Practice." *Nature Reviews Immunology* 20(11): 651–68.
59. Wang, Shuyue, Kun Xie, and Tengfei Liu. 2021. "Cancer Immunotherapies: From Efficacy to Resistance Mechanisms – Not Only Checkpoint Matters." *Frontiers in Immunology* 12.